Risedronate inhibits human osteosarcoma cell invasion

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Osteosarcoma is a highly malignant bone tumor common in children and adolescents, often leading to pulmonary metastases.
• Matrix metalloproteinases (MMPs) are implicated in tumor invasion, and MMP-inhibitors are under clinical investigation.
• Bisphosphonates (BPs) are established treatments for bone resorption and have shown antitumor effects in various cancers.

Purpose of the Study:

• To investigate the effect of risedronate on the invasiveness of osteosarcoma cell lines.
• To determine if risedronate affects the expression and activity of MMP-2 and MMP-9 in osteosarcoma cells.

Main Methods:

• Osteosarcoma cell lines (SaOS-2, U2OS) were treated with varying concentrations of risedronate.
• Cell viability was assessed using MTT assay.
• MMP-2 and MMP-9 levels (mRNA, protein), activity, and cellular invasion were analyzed.

Main Results:

• Risedronate significantly reduced osteosarcoma cell invasiveness in a dose-dependent manner.
• No cytotoxicity was observed at effective risedronate concentrations.
• Risedronate suppressed mRNA, protein levels, and gelatinolytic activity of MMP-2 and MMP-9.

Conclusions:

• Risedronate demonstrates potential in reducing osteosarcoma cell invasion.
• The suppression of MMP-2 and MMP-9 by risedronate may contribute to its anti-invasive effects in osteosarcoma.